BD® HD Check System

BD HD Check System Doxorubicin Assay Cartridges

Icon to close the modal
Becton Dickinson Australia & New Zealand
Phone Icon
AU: 1800 656 100
NZ: 0800 572 468
Modal Close Icon
Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
For more information, please visit our Contact Us page

Anyone who handles hazardous drugs (HDs) during transportation, preparation, administration or waste disposal may be at risk. A Canadian study of six hospitals found that frequently contacted surfaces at every stage of the hospital medication system had measurable levels of antineoplastic drug contamination.9

The revolutionary BD® HD Check System has a convenient handheld design that enables testing for select HDs at any location. It provides reliable, easy-to-read results in less than 10 minutes, so you can take immediate corrective action and prevent HD residue from spreading. 

See how >

Features and Benefits
Promotional Story

GTIN - Case



GTIN - Each



Case Quantity



GTIN - Case 50382905150253 1
GTIN - Each 00382905150258 1


Case Quantity 20
Electronic Instructions for Use (eIFUs)
Frequently Asked Questions
Related Products
  1. Hazardous drug exposures in healthcare. Centers for Disease Control and Prevention website. www.cdc.gov/niosh/topics/hazdrug/. Published September 27, 2018. Accessed December 2, 2019.
  2. Cavallo D, Ursini CL, Perniconi B, et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res. 2005;587(1-2):45–51.
  3. McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010;52(10):1028– 34.
  4. Skov T, Maarup B, Olsen J, et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992;49(12):855–861.
  5. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994;20(1):22–26.
  6. Sotaniemi EA, Sutinen S, Arranto AJ, et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand. 1983;214(3):181–189.
  7. Nurses’ Health and Workplace Exposures to Hazardous Substances. Study conducted by Environmental Working Group, Health Care Without Harm, American Nurses Association, Environmental Health Education Center at University of Maryland School of Nursing. Environmental Working Group website. http://www.ewg.org/research/nurseshealth/nurses-exposure Published December 11, 2007. Accessed January 24, 2017.
  8. Hemminki K, Kyronen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985; 39(2): 141–147.
  9. Hon CY, Teschke K, Chu W, Demers P, Venners S. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. J Occup Environ Hyg. 2013;10(7):374-83. doi: 10.1080/15459624.2013.789743.
  10. Connor TH, Zock MD, Snow AH. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations. J Occup Environ Hyg. 2016;13(9):658-687. doi: 1080/15459624.2016.1165912.
  11. Gabay M, Johnson P, Fanikos J, et al. Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. Am J Health Syst Pharm. 2021;78(17):1568-1575. doi:10.1093/ajhp/zxab134
  12. Valero-García S, González-Haba E, Gorgas-Torner MQ, et al. Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH). Farm Hosp. 2021;45(2):96-107. doi:10.7399/fh.11655
  13. Domingo T, Fontán G, Enríquez M, et al. Guide for monitoring surfaces for hazardous drug contamination. 1st ed. Instituto Español de Investigación Enfermera; Consejo General de Enfermería; 2021.
  14. Valero García S, Centelles-Oria M, Palanques-Pastor T, Vila Clérigues N, López-Briz E, Poveda Andrés JL. Analysis of chemical contamination by hazardous drugs with BD HD Check® system in a tertiary hospital. J Oncol Pharm Pract. 2021;10781552211038518. doi: 10.1177/ 10781552211038518
  15. Kiffmeyer TK, Tuerk J, Hahn M, et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies–the MEWIP project. Ann Occup Hyg. 2013;57(4):444–455. doi:10.1093/annhyg/mes081.
  16. Salch SA, Zamboni WC, Zamboni BA, Eckel SF. Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies. Am J Health Syst Pharm. 2019;76(9):591-598. doi:10.1093/ajhp/zxz033
  17. United States Pharmacopeial Convention (USP). USP general chapter <800>. Hazardous drugs – handling in healthcare settings. Rockville, MD: United States Pharmacopeial Convention. DocID: GUID-5D76173F-5CB6-47B8-815E-7C275A916085_7_en-US
  18. Wipe Analysis. Pharmacy Purchasing & Products. https://www.pppmag.com/article/2525. Published March 2020. Accessed May 21, 2021.
  19. Massoomi F. HD Check-In An interview with HD safety expert Fred Massoomi, RPh, PharmD, FASHP. BD-7875. 2018.

BD-5894 (09/22)